Cardiovascular disease: risk assessment and reduction, including lipid modification

treatment 1.9.1 If the lipid target for primary or secondary prevention of CVD (see recommendation 1.6.1 and recommendation 1.7.1) is not met: • discuss adherence and timing of statin dose with the person • encourage them to continue improvements to their diet and lifestyle, and to make further changes if appropriate • consider increasing the statin intensity/dose if the person is not currently taking a high-intensity statin at the maximum tolerated dose. [May 2023, amended December 2023] 1.9.2 If the person reports adverse effects when taking a high-intensity statin, discuss the following strategies with them: • stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin • changing to a different statin in the same intensity group (rosuvastatin if already receiving atorvastatin) • reducing the dose • changing to a lower-intensity statin. [2014, amended May 2023 and December 2023] 1.9.3 If a person is not able to tolerate a high-intensity statin, aim to treat with the maximum tolerated intensity and dose of statin. [2014, amended December 2023] 1.9.4 Advise the person that any statin at any dose reduces CVD risk. [2014, amended May 2023 and December 2023] For a
